Hims Hers Health Inc (HIMS)
Official siteHEALTHCARE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $4.62B
Last updated: Nov 17, 2026 at 11:06 AM ET
Hims Hers Health Inc (HIMS) Financials: Revenue, Profit and Cash Flow
Hims Hers Health reported revenue of $2.35B for the fiscal year ended Dec 31, 2025, up 59.0% from the year before. That year, net income was $128.37M with a net margin of 5.5%, operating cash flow was $300.01M and free cash flow was $57.41M. The quarter ended Sep 30, 2026 had revenue of $890.37M and net income of -$33.04M.
Revenue and Margins
The operating margin was 4.5% in the fiscal year ended Dec 2025, the highest of the 7 years shown with an operating margin. Over the 7 years to Dec 2025, revenue grew from $26.68M, a compound annual rate of 89.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.35B | +59.0% | 73.8% | 4.5% | 5.5% |
| Dec 2024 | $1.48B | +69.3% | 79.5% | 4.2% | 8.5% |
| Dec 2023 | $872.00M | +65.5% | 82.0% | -3.4% | -2.7% |
| Dec 2022 | $526.92M | +93.8% | 77.6% | -13.0% | -12.5% |
| Dec 2021 | $271.88M | +82.8% | 75.2% | -42.3% | -39.6% |
| Dec 2020 | $148.76M | +80.2% | 73.6% | -10.2% | -12.2% |
| Dec 2019 | $82.56M | +209.4% | 54.0% | -90.1% | -87.3% |
| Dec 2018 | $26.68M | N/A | 29.2% | -284.0% | -282.0% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872.00M | $526.92M | $271.88M | $148.76M | $82.56M | $26.68M |
| Cost of revenue | $614.26M | $303.38M | $157.05M | $118.19M | $67.38M | $39.31M | $37.95M | $18.88M |
| Gross profit | $1.73B | $1.17B | $714.95M | $408.72M | $204.49M | $109.45M | $44.60M | $7.80M |
| Research and development | $149.30M | $78.82M | $48.23M | $29.24M | $22.38M | $11.24M | $0 | $0 |
| Operating income | $105.61M | $61.90M | -$29.45M | -$68.70M | -$115.04M | -$15.14M | -$74.41M | -$75.77M |
| Net income | $128.37M | $126.04M | -$23.55M | -$65.68M | -$107.66M | -$18.11M | -$72.06M | -$75.24M |
| EBITDA | $180.92M | $84.44M | -$17.74M | -$58.09M | -$104.41M | N/A | -$71.47M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $890.37M | $753.21M | $608.10M | $617.82M | $598.98M | $544.83M | $586.01M | $481.14M | $401.56M | $315.65M | $278.17M | $246.62M |
| Gross profit | $509.20M | $480.80M | $396.79M | $444.44M | $442.06M | $416.20M | $430.69M | $369.54M | $317.89M | $256.61M | $229.09M | $204.06M |
| Operating income | -$66.15M | -$97.19M | -$78.32M | $9.19M | $11.81M | $26.72M | $57.90M | $18.60M | $22.37M | $11.03M | $9.90M | -$400.00K |
| Net income | -$33.04M | -$86.29M | -$92.11M | $20.60M | $15.77M | $42.51M | $49.48M | $26.02M | $75.59M | $13.30M | $11.13M | $1.25M |
Balance Sheet
As of Dec 2025, total debt of $977.42M exceeded cash and equivalents by $748.81M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.15B | $707.54M | $441.19M | $366.34M | $420.58M | $118.70M | $204.77M | $47.52M |
| Current assets | $767.64M | $395.83M | $265.05M | $216.59M | $269.90M | $113.08M | $1.66M | $47.34M |
| Cash and equivalents | $228.62M | $220.58M | $96.66M | $46.77M | $71.78M | $27.34M | $1.51M | $41.50M |
| Total liabilities | $1.61B | $230.82M | $97.16M | $54.60M | $85.97M | $15.61M | $8.17M | $24.73M |
| Short-term debt | $4.84M | $0 | $7.41M | $0 | $42.83M | $0 | $1.51M | $7.78M |
| Long-term debt | $972.58M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $540.93M | $476.72M | $344.03M | $311.74M | $334.62M | -$146.87M | $5.00M | $22.79M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.55B | $3.63B | $2.27B | $2.15B | $2.23B | $1.88B | $891.71M | $707.54M | $602.26M | $480.50M | $448.11M | $441.19M |
| Total liabilities | $3.19B | $3.30B | $1.82B | $1.61B | $1.65B | $1.31B | $342.45M | $230.82M | $162.21M | $118.53M | $103.62M | $97.16M |
| Cash and equivalents | $605.60M | $609.81M | $222.27M | $228.62M | $345.78M | $1.12B | $273.74M | $220.58M | $165.52M | $129.29M | $105.24M | $96.66M |
| Shareholder equity | $355.30M | $324.07M | $446.17M | $540.93M | $580.98M | $562.70M | $549.26M | $476.72M | $440.05M | $361.97M | $344.48M | $344.03M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 19.1% of operating cash flow. Share repurchases came to 156.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $300.01M | $251.08M | $73.48M | -$26.53M | -$34.41M | -$2.48M | -$74.87M | -$57.32M |
| Capital expenditures | $242.59M | $52.75M | $26.49M | $7.25M | $5.01M | $4.23M | $1.79M | $8.00K |
| Free cash flow | $57.41M | $198.33M | $46.99M | -$33.78M | -$39.42M | -$6.71M | -$76.65M | -$57.33M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $1.74M | N/A | N/A |
| Share repurchases | $89.96M | $83.04M | $2.00M | $0 | $34.88M | $3.36M | $0 | N/A |
| Investing cash flow | -$1.02B | -$19.05M | -$12.11M | $34.70M | -$156.27M | -$39.70M | -$39.30M | -$8.00K |
| Financing cash flow | $729.62M | -$107.84M | -$11.47M | -$33.13M | $235.04M | $47.74M | $95.32M | $78.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $65.39M | -$35.94M | $89.36M | $61.31M | $148.72M | -$19.12M | $109.09M | $86.39M | $85.27M | $53.59M | $25.84M | $21.98M |
| Capital expenditures | $39.42M | $32.25M | $36.32M | $63.88M | $69.36M | $50.31M | $59.04M | $26.89M | $5.88M | $6.03M | $13.96M | $11.20M |
| Free cash flow | $25.97M | -$68.19M | $53.03M | -$2.57M | $79.36M | -$69.43M | $50.05M | $59.50M | $79.39M | $47.57M | $11.88M | $10.79M |
Frequently Asked Questions About HIMS
What is Hims Hers Health's annual revenue?
Hims Hers Health reported revenue of $2.35B for the fiscal year ended Dec 31, 2025.
How fast is Hims Hers Health's revenue growing?
Revenue was up 59.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 64.5%.
Is Hims Hers Health profitable?
Yes. Hims Hers Health reported net income of $128.37M for the fiscal year ended Dec 31, 2025, with a net margin of 5.5%.
How much free cash flow does HIMS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $300.01M minus capital expenditures of $242.59M produced free cash flow of $57.41M.
How much debt does Hims Hers Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $972.58M, short-term debt of $4.84M and cash and equivalents of $228.62M.
HIMS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors